Is immunotherapy in the future of therapeutic management of sarcomas?

Sarcomas are rare, ubiquitous and heterogeneous tumors usually treated with surgery, chemotherapy, target therapy, and radiotherapy. However, 25–50% of patients experience local relapses and/or distant metastases after chemotherapy with an overall survival about 12–18 months. Recently, immuno-therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Clemente, Ottavia, Ottaiano, Alessandro, Di Lorenzo, Giuseppe, Bracigliano, Alessandra, Lamia, Sabrina, Cannella, Lucia, Pizzolorusso, Antonio, Di Marzo, Massimiliano, Santorsola, Mariachiara, De Chiara, Annarosaria, Fazioli, Flavio, Tafuto, Salvatore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077947/
https://www.ncbi.nlm.nih.gov/pubmed/33902630
http://dx.doi.org/10.1186/s12967-021-02829-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077947/
https://www.ncbi.nlm.nih.gov/pubmed/33902630
http://dx.doi.org/10.1186/s12967-021-02829-y

Ejemplares similares